| Catalog No. | Size | Price (USD) |
| 10336-RP01-100 | 100 µL | $147.96 |
| 10336-RP01-200 | 200 µL | $251.64 |
| 10336-RP01-400 | 400 µL | $355.32 |
General Information
| Product name | Anti-Interferon alpha 4/IFNA4 Antibody, Rabbit Polyclonal |
| Validated applications | ELISA (FAQ Protocol) |
| Species reactivity | Reacts with: Human |
| Specificity | Human Interferon alpha 4/IFNA4 |
| Immunogen | Recombinant Human IFNA4 Protein (Catalog#10336-H08B) |
| Preparation | Produced in rabbits immunized with purified, recombinant Human IFNA4 (rh IFNA4; Catalog#10336-H08B; NP_066546.1; Met1-Asp189). Total IgG was purified by Protein A affinity chromatography. |
| Source | Polyclonal Rabbit IgG |
| Purification | Protein A |
| Formulation | 0.2 μm filtered solution in PBS |
| Conjugate | Unconjugated |
| Form | Liquid |
| Shipping | This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Storage | This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles. |
Synonyms: Anti-IFN-alpha4a Antibody; Anti-INFA4 Antibody; Anti-MGC142200 Antibody
Background Information
| Full Name | interferon, alpha 4 |
| Description | Interferon, alpha 4 (IFNA4) belongs to the alpha/beta interferon family. Two variants of IFNA4 (IFNA4a and IFNA4b) are known, which differ from each other by changes in their coding regions at nucleotide positions 220 and 410 and can be distinguished by selective restriction enzyme analysis. Interferons are produced by macrophages, IFN-alpha has antiviral activities. Interferon stimulates the production of two enzymes: a protein kinase and an oligoadenylate synthetase. IFN-alpha, the first cytokine to be produced by recombinant DNA technology, has emerged as an important regulator of growth and differentiation, affecting cellular communication and signal transduction pathways as well as immunological control. Originally discovered as an antiviral substance, the efficacy of IFN-alpha in malignant, viral, immunological, angiogenic, inflammatory, and fibrotic diseases suggests a spectrum of interrelated pathophysiologies. IFN-alpha emerged as a prototypic tumor suppressor protein that represses the clinical tumorigenic phenotype in some malignancies capable of differentiation. |
| References |
|
